Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SRRK logo SRRK
Upturn stock ratingUpturn stock rating
SRRK logo

Scholar Rock Holding Corp (SRRK)

Upturn stock ratingUpturn stock rating
$37.44
Last Close (24-hour delay)
Today's Top Performer Top performer
Profit since last BUY13.42%
upturn advisory
Strong Buy
BUY since 21 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: SRRK (5-star) is a STRONG-BUY. BUY since 21 days. Profits (13.42%). Updated daily EoD!

Upturn Star Rating

rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

rating

10 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $49.67

1 Year Target Price $49.67

Analysts Price Target For last 52 week
$49.67 Target price
52w Low $6.76
Current$37.44
52w High $46.98

Analysis of Past Performance

Type Stock
Historic Profit 180.2%
Avg. Invested days 36
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.55B USD
Price to earnings Ratio -
1Y Target Price 49.67
Price to earnings Ratio -
1Y Target Price 49.67
Volume (30-day avg) 10
Beta 0.3
52 Weeks Range 6.76 - 46.98
Updated Date 07/12/2025
52 Weeks Range 6.76 - 46.98
Updated Date 07/12/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.55

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -50.15%
Return on Equity (TTM) -106.71%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3253529841
Price to Sales(TTM) 13.14
Enterprise Value 3253529841
Price to Sales(TTM) 13.14
Enterprise Value to Revenue 8.22
Enterprise Value to EBITDA -2.08
Shares Outstanding 94945600
Shares Floating 79233021
Shares Outstanding 94945600
Shares Floating 79233021
Percent Insiders 4.35
Percent Institutions 118.63

ai summary icon Upturn AI SWOT

Scholar Rock Holding Corp

stock logo

Company Overview

overview logo History and Background

Scholar Rock Holding Corp. is a biopharmaceutical company focused on discovering and developing medicines for the treatment of serious diseases in which protein growth factors play a fundamental role. Founded in 2012, the company is headquartered in Cambridge, Massachusetts. Scholar Rock's approach targets the molecular mechanisms of growth factor activation for greater therapeutic selectivity and efficacy.

business area logo Core Business Areas

  • TGFu03b2 Inhibitors: Focuses on developing inhibitors of Transforming Growth Factor beta (TGFu03b2) superfamily proteins to treat diseases characterized by fibrosis, muscle atrophy, and anemia.
  • SRK-181: SRK-181 is a selective inhibitor of latent myostatin activation designed to treat spinal muscular atrophy (SMA).

leadership logo Leadership and Structure

Nagesh Mahanthappa is the President and CEO. The company has a board of directors that provides strategic oversight. The organizational structure includes research and development, clinical development, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • Apitegromab: A selective inhibitor of myostatin activation. Focuses on treatment of Spinal Muscular Atrophy (SMA). The drug is currently in clinical development. There is no current market share data available, it is in Phase 3 clinical trial. Competitors include Biogen, Roche, and Novartis who already have approved SMA treatments.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by lengthy and expensive development processes, stringent regulatory requirements, and significant patent protection.

Positioning

Scholar Rock is positioned as a company focused on growth factor biology with a pipeline of targeted therapies. Its competitive advantage lies in its proprietary platform for selective inhibition of growth factor activation.

Total Addressable Market (TAM)

The total addressable market is variable, but for Spinal Muscular Atrophy (SMA) treatments, it is projected to be in the billions of dollars. Scholar Rock is positioning itself within this TAM by developing a novel myostatin inhibitor to address unmet needs in SMA treatment.

Upturn SWOT Analysis

Strengths

  • Proprietary technology platform targeting growth factor activation
  • Strong scientific team with expertise in growth factor biology
  • Focused pipeline addressing unmet medical needs
  • Partnerships with leading research institutions

Weaknesses

  • Limited commercial infrastructure as a development-stage company
  • Dependence on successful clinical trial outcomes
  • High cash burn rate
  • Reliance on external funding

Opportunities

  • Potential to expand pipeline through internal research and development
  • Partnerships with larger pharmaceutical companies for commercialization
  • Expansion into new therapeutic areas
  • Positive clinical trial results driving stock value

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Changes in healthcare reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • Biogen (BIIB)
  • Roche (RHHBY)
  • Novartis (NVS)

Competitive Landscape

Scholar Rock's advantages lie in its targeted approach to growth factor inhibition. Disadvantages include its limited commercial resources compared to larger pharmaceutical companies. Current market share for SRRK is effectively zero as they do not yet have an approved product.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by increasing R&D expenses and clinical trial advancements.

Future Projections: Future growth is contingent on successful clinical trial outcomes and partnerships.

Recent Initiatives: Recent initiatives include advancing apitegromab into Phase 3 clinical trials and seeking partnerships.

Summary

Scholar Rock is a development-stage biopharmaceutical company focusing on growth factor inhibition. Its strength lies in its novel technology and pipeline, but weaknesses include limited commercial infrastructure and dependence on clinical trial outcomes. Positive clinical trial results and partnerships are crucial for its success, while regulatory hurdles and competition pose significant risks. The company's future is uncertain given its R&D nature.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual risk tolerance and due diligence. Market share data is approximate and based on available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Scholar Rock Holding Corp

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2018-05-24
CEO & Chairman of the Board Mr. David L. Hallal
Sector Healthcare
Industry Biotechnology
Full time employees 128
Full time employees 128

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.